Most Read Articles
Tristan Manalac, 6 days ago
Left ventricular assist devices (LVADs) can reverse pulmonary hypertension secondary to left heart disease regardless of baseline pulmonary vascular resistance, according to a new study.
Yesterday
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
11 May 2019
Acute kidney injury (AKI) commonly occurs within a year after cancer diagnosis in paediatric patients and is tied to long-term deteriorations in renal function, a recent study has found.
11 May 2019
Women practicing exclusive breastfeeding for 6 months achieve greater postpartum weight loss compared with those exclusively breastfeeding for a shorter duration, according to data from the MILK* study.

Cangrelor a potential treatment for PCI patients unable to take oral meds

18 Mar 2019

Patients undergoing urgent/emergent percutaneous coronary intervention (PCI) and unable to take oral medications are good candidates for treatment with cangrelor, according to a new meta-analysis.

A pooled analysis of three clinical trials, resulting in a cumulative sample of 24,910 patients, showed that after 48 hours, cangrelor reduced the odds of the primary composite outcome (death, myocardial infarction, ischaemia-driven revascularization or stent thrombosis) by 19 percent (3.8 percent for cangrelor vs 4.7 percent for control; odds ratio [OR], 0.81; 95 percent CI, 0.71–0.91; p=0.007).

Similarly, cangrelor decreased the risk of the secondary outcome of stent thrombosis (OR, 0.59; 0.43–0.80; p=0.0008) and of the secondary composite outcome of death, myocardial infarction and ischaemia-driven revascularization (OR, 0.81; 0.71–0.92; p=0.0014).

The same was true for the risk of the composite of death, Q-wave myocardial infarction and stent thrombosis (OR, 0.63; 0.49–0.81; p=0.0002).

Taking each component of the primary composite outcome independently, cangrelor similarly resulted in significantly reduced odds of ischaemia-driven revascularization (OR, 0.71; 0.52–0.98; p=0.0363) and myocardial infarction (OR, 0.85; 0.74–0.97; p=0.0182).

In contrast, while the death count was lower in those who were on cangrelor medication (0.3 percent vs 0.4 percent), there was no significant difference in risk (OR, 0.73; 0.47–1.15; p=0.1694).

Cangrelor was also relatively safe and well-tolerated, despite a potential side-effect of over-inhibition of the platelet P2Y12 pathway, said researchers. The clinical benefits associated with cangrelor was not hampered by increased risks of severe bleeding and moderate bleeding, or the need for blood transfusion.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 6 days ago
Left ventricular assist devices (LVADs) can reverse pulmonary hypertension secondary to left heart disease regardless of baseline pulmonary vascular resistance, according to a new study.
Yesterday
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
11 May 2019
Acute kidney injury (AKI) commonly occurs within a year after cancer diagnosis in paediatric patients and is tied to long-term deteriorations in renal function, a recent study has found.
11 May 2019
Women practicing exclusive breastfeeding for 6 months achieve greater postpartum weight loss compared with those exclusively breastfeeding for a shorter duration, according to data from the MILK* study.